HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies
HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines, and Shanghai Henlius Biotech, Inc., a global biopharmaceutical...
WholisticResearch Reveals the Best Nootropics of 2023
In-depth Analysis and Testing Unveil the Leading Brain-Boosting Supplements WholisticResearch, a leading authority in the realm of cognitive enhancement research, has recently unveiled its...
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced the interim results for the six months ended 30 June 2023 (the period...
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced that a phase 1/2 clinical trial of EB12-20145P (HLX04-O), a recombinant anti-VEGF humanised...
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to...
HanchorBio Received IND Approval of HCB101 Multi-Regional Clinical Trial By Taiwan FDA HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today...
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion...
RenovoRx, Inc. ("RenovoRx") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd ("Imugene") (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic...
ADICON Holdings Limited One of the Top Three ICL Service Providers in China is...
Serving Patients and the General Public with High-quality Testing Services and Being a Trusted and Reliable Partner ADICON Holdings Limited (ADICON or Company, HKG: 9860),...
ADICON Announces Proposed Listing on the Main Board of The Stock Exchange of Hong...
ADICON Holdings Limited (ADICON or Company, HKG: 9860), the pioneer of independent clinical laboratory (ICL) and one of the top three ICL service providers...
Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and...
Avance Clinical, the leading award-winning Australian and North American CRO that offers ClinicReady and GlobalReady for early phase biotech companies to speed up the...
Avance Clinical Joins Global Health Summit Campaign for Faster Access to Life-Changing and Life-Saving...
Avance Clinical the leading award-winning Australian and North American CRO that offers the programs ClinicReady and GlobalReady for early phase biotech companies to speed...
EC Healthcare Signs Sustainability-Linked Syndicated Facility, A Ground-breaking Achievement in Hong Kong Healthcare Industry
EC Healthcare (the Company, which together with its subsidiaries is referred to as the Group, HKG: 2138), the largest non-hospital medical group in Hong...
Avance Clinical CEO Joins Global BioPharma Panel for Evolution Europe Summit 2023
Avance Clinical the leading award-winning Australian and North American biotech CRO that offers a GlobalReady program to early phase biotech companies to speed up...
HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat...
HanchorBio Received IND Clearance of HCB101 Multi-regional Clinical Trial By US FDA HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that...
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
Essex Bio-Technology Ltd. (Essex or the Group, HKG: 1061) is pleased to announce that its wholly-owned subsidiary, Majeton Pte. Ltd. (Majeton), has entered into...
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in...
Essex Bio-Technology Ltd. (Essex or the Group, HKG: 1061) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai) Co., Ltd. (Essex Medipharma),...
TrialWire Patient Recruitment Platform Launches AI Pre-recruit to Cut Recruitment Time by 50%
The award-winning TrialWire(TM) Patient Recruitment Platform, the most secure and rapid digital patient recruitment solution to reverse failing recruitment, today announced the rollout of...
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of...
Apollomics' Class A ordinary shares and public warrants are expected to begin trading today on the Nasdaq Capital Market under the ticker symbols...
Singapore family cord blood bank Cryoviva upgrades to AXP II System for cord blood...
Cryoviva Singapore, reputed to be among the top family cord stem cell banking companies in Southeast Asia, is making a significant upgrade to its...
Essex Bio-Technology Announces 2022 Annual Financial Results
Resilience & Relevance, Growth Ready Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced the annual results for the year ended 31...
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for...
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced that two of its wholly-owned subsidiaries, Essex Bio-Investment Limited (Essex Bio-Investment) and Zhuhai...